01 POLIO Brooks 508
Document text
Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention National Center for Immunization and Respiratory Diseases Photographs and images included in this presentation are licensed solely for CDC/NCIRD online and presentation use. No rights are implied or extended for use in printing or any use by other CDC CIOs or any external audiences.Polio Vaccine Work Group Oliver Brooks, MD, FAAP ACIP Meeting February 28, 2024 nOPV2 ▪Considerations for the potential use of novel type 2 oral poliovirus vaccine (nOPV2) as an outbreak control measure in the United States fIPV ▪Clinical considerations for children who received fractional dose inactivated polio vaccine ( fIPV) in other countriesPolio Vaccination Work Group Terms of Reference Policy topics under consideration: